The China Alzheimer Report 2022
Rujing Ren,Jinlei Qi,Shaohui Lin,Xinya Liu,Peng Yin,Zhihui Wang,Ran Tang,Jintao Wang,Qiang Huang,Jianping Li,Xinyi Xie,Yongbo Hu,Shishuang Cui,Yuan Zhu,Xiaoping Yu,Pengfei Wang,Yikang Zhu,Yiran Wang,Yanyan Huang,Yisong Hu,Ying Wang,Chunbo Li,Maigeng Zhou,Gang Wang
DOI: https://doi.org/10.1136/gpsych-2022-100751
2022-02-01
General Psychiatry
Abstract:China’s population has rapidly aged over the recent decades of social and economic development as neurodegenerative disorders have proliferated, especially Alzheimer’s disease (AD) and related dementias (ADRD). AD’s incidence rate, morbidity, and mortality have steadily increased to make it presently the fifth leading cause of death among urban and rural residents in China and magnify the resulting financial burdens on individuals, families and society. The ‘Healthy China Action’ plan of 2019–2030 promotes the transition from disease treatment to health maintenance for this expanding population with ADRD. This report describes related epidemiological trends, evaluates the economic burden of the disease, outlines current clinical diagnosis and treatment status and delineates existing available public health resources. More specifically, it examines the public health impact of ADRD, including prevalence, mortality, costs, usage of care, and the overall effect on caregivers and society. In addition, this special report presents technical guidance and supports for the prevention and treatment of AD, provides expertise to guide relevant governmental healthcare policy development and suggests an information platform for international exchange and cooperation.